An interventional study of Fluoxetine and Placebo in Depression in Adolescence, Antidepressant Activity in Healthy Volunteers and Healthy Adult Participants, sponsored by University of Oxford. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by University of Oxford · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.
Among the 43 studies testing fluoxetine in Depression, this one is the 24th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 42nd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18–24 · Healthy volunteers
University of Bern · Sites in Zimbabwe
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Federal University of Latin American Integration · Sites in Brazil
Ages 25–65 · Healthy volunteers
By country, each count listing its studies:
Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 24 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 9 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 97 across the 42 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 43 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
41 studies in Depression by University of Oxford: 12 open now, 12 under way, none of them phase 3. Of 22 finished, 0 (0%) have results posted.
Among the 41 studies in Depression by University of Oxford, this one is the 17th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 33 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 37th registered.
University of Oxford’s Depression studies by the year they started, since 2004.
6 of the studies testing fluoxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424781University of OxfordFluoxetine on Emotional Experience (FLEX) Study | 2026-12-31 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
| NCT05976347Wake Forest University Health SciencesIdentifying and Treating Depression in the Orthopaedic Trauma Population | 2027-05 |
| NCT07456501University of OxfordFluoxetine and Understanding Social Experiences | 2027-07-20 |
| NCT07110831University of IbadanDisposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies testing fluoxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University of Oxford’s 41 in Depression:
This tab as a report to print or save as PDF → With an account.
Adolescence is a critical developmental period marked by significant social, cognitive, and emotional changes. Unfortunately, it is also a time when the risk of depression and anxiety rises dramatically. Early, effective treatment is essential to mitigate long-term impacts on relationships, education, and life satisfaction. While psychological therapies are recommended as first-line treatment for mild to moderate depression in young people, antidepressant use (particularly SSRIs such as Prozac) has risen sharply, especially among girls aged 15-17.
Despite their widespread use, there is limited research on how SSRIs address adolescent depression, leaving clinicians with little evidence to guide treatment decisions. The Fluoxetine and Understanding Social Experiences (FUSE) study aims to shed light on how Prozac (medically known as fluoxetine) influences decision-making in healthy young people in four key areas that are known to be affected by depression: emotional processing (e.g., facial expression recognition), social function (e.g., sensitivity to peer rejection), reward processing (e.g., how people learn from rewards and punishments), and motivation (e.g., how people make decisions about whether a certain outcome or reward is worth the effort to obtain). Some of the tests employed in the study use facial expression and heart-rate recording as aditional measures. We are aiming to recruit and test 80 young people between the ages of 18 and 24.
When included in the study, participants are randomly assigned to receive either a weeklong treatment with fluoxetine, or a placebo (a pill with no active ingredients). The study follows a double-blind design, which means that neither the researchers nor the participants are aware of the treatment received so as to not influence the results.
We belive that fluoxetine will have beneficial effects on social decision-making in young people, which might manifest as increased accuracy labelling positive facial expressions, less sensitivity to negative feedback, lower self-reported negative mood in response to social exclusion and reduced heart rate/negative facial expressivity in response to unpleasant social experiences.
The FUSE study aims to deepen our understanding of how antidepressants affect decision-making in young people, at a time when antidepressant prescriptions have risen but research is scarce. By identifying the exact domains of functioning which are affected by antidepressant use in this age group, this research will help inform which young people are likely to benefit most from drug treatment.
The project results will be published in peer-reviewed journals and presented at academic conferences. We are also working with a group of young advisors who will help us decide how to best share our results with others in their age group. A brief summary of the study findings will also be provided to participants who would like to receive it. All research data, excluding information that could identify participants, will be stored safely for at least 10 years after final publication or public release.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Psychiatric History:
Lifestyle:
Physical Health:
Medical History:
Prior Study Participation:
Other considerations:
•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's safety or ability to participate in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluoxetine
Drug: Placebo
Participants will be taking a 20mg fluoxetine capsule daily for 7 days.
Participants will be taking a placebo capsule daily for 7 days.
Behavioural measure: Facial Expression Recognition Task (FERT)
Recognition of positive (happy, surprise) faces in the Facial Expression Recognition Task.
Time frame: On the last day of the 7-day treatment
Self-report measure: the Need Threat Scale
Participant scores on the 20-item Need Threat Scale, administered after the Cyberball task (an ostracism paradism). The scale ssesses self-reported current satisfaction levels with belonging, self-esteem, meaningful existence, and control on 7-point scales ranging from 1 (do not agree) to 7 (agree), serving as a proxy of whether these needs are threatened.
Time frame: On the last day of the 7-day treatment
Behavioural measure: Probabilistic Reversal Learning Task
Performance on a probabilistic reversal learning task, in which participants learn probabilistic reward contingencies associated with three stimulus images, and them must relearn when those contingencies are reversed.
Time frame: On the last day of the 7-day treatment
Behavioural measure: Piggybank Task
Performance on a task measuring action vigour, where participants have to earn monetary rewards by pressing keys to "shake" coins from virtual piggy banks. Piggybanks vary in effort and reward, requiring ongoing adjustment.
Time frame: On the last day of the 7-day treatment
Self-report measure: Perception of social rejection on the Verbal Interaction Social Threat (VIST) Task
In the Verbal Interaction Social Threat Task, participants are led to believe they will be engaging in an online interaction with two other study participants. Participants are shown a series of prompts and, for each one, choose one of four possible "icebreaker" sentences (for example, under the theme of sport: "I play a team sport such as football, rugby or netball" or "I play an individual sport like tennis or athletics"). After each choice, they receive responses that appear to be typed in real time by the two peers. In reality, these responses are pre-programmed and skewed toward negative feedback for most prompts (e.g., a peer might reply "I think team sports are more like a game than a real sport"). Following each exchange, participants rate how positively or negatively they perceived the interaction.
Time frame: On the last day of the 7-day treatment
Behavioural measure: Proportion of anger-related solutions found on the Word Completion Task
In this task, participants complete word puzzles with multiple solutions, many allowing aggression-related words (e.g., k n \_ \_ \_ as "knees" or "knife"). It follows the VIST rejection paradigm, which is expected to reduce social cohesion and increase anti-social thought.
Time frame: On the last day of the 7-day treatment
Physiological measure: Heart Rate Variability in response to social rejection
Heart rate variability measures across tasks inducing social rejection.
Time frame: On the last day of the 7-day treatment
Physiological measure: Facial Expression in response to social rejection
Video recordings that identify facial expressions across tasks inducing social rejection.
Time frame: On the last day of the 7-day treatment
Plan to share: Yes — Data which has been fully de-identified and relevant supporting materials (e.g., study protocol, data dictionary, and analysis documentation) may be shared with other academic organisations in the future, including those outside of the UK and the EU. Participants will be informed of this and specific consent for this will be obtained.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available within 6 months of data collection completion (end 2027).
Access criteria: Fully de-identified individual participant data (IPD) and relevant supporting documentation may be shared with academic researchers for scientific research purposes. Access will be limited to researchers affiliated with recognised academic or research institutions, including those outside of the UK and EU. Approved researchers will be granted access only to fully de-identified IPD and relevant supporting materials. Data will be shared via secure transfer methods or through a controlled-access data repository.
Start is estimated for Mar 2026; primary completion for Jul 2027, 16 months later.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 16 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluoxetine